【摘要】 目的前瞻性评估微粒化纯化的黄酮成分 (爱脉朗 )治疗慢性静脉功能不全 (chronicve nousinsufficiency ,CVI)的疗效。方法按预先制定的标准 ,随机选择 133例CVI患者。其中 ,研究前曾用其他药物治疗者 34例 (2 7 6 % ) ,有合并症者 38例 (2 8 8% )。对入选患者进行CVI分级、临床症状和体征的治疗前评估 ,然后予以口服微粒化纯化的黄酮成分 5 0 0mg/次 ,2次 /d治疗。在治疗后15、30和 6 0d进行测定和记录 ,最后进行统计学分析。结果治疗前后患者的肢体肿胀、沉重、痉挛和疼痛程度等症状和体征有明显的改善并具有统计学意义。结论微粒化纯化的黄酮成分能有效地改善CVI的临床症状和体征更多还原

【Abstract】 ObjectiveTo prospectively evaluate the therapeutic effect of Alvenor on symptoms and signs of chronic venous insufficiency of lower extremities.MethodAccording to preset criteria, 133 patients from 8 hospitals in Hangzhou, Beijing, Guanzhou and Shanghai were recruited into this study including 78 males (58.6%) and 55 females (41.4%). The average age was 23～77 (55±13) years. The illness course was from 1～50 years with a mean of (11±11) yrs. Other therapeutic modalities were adopted in 34 before inclusion into this study and 38 cases (28.8% ) had suffered from certain complications. Classification was first defined when the patient was enrolled and clinical symptoms and signs were evaluated. Alvenor was given 500?mg, twice a day orally. Reevaluation and record by the same criteria was carried out 15, 30, and 60 days after treatment, and statistical analysis was conducted. ResultsSwelling, heaviness, spasm, and pain, etc, were statistically improved. ConclusionsAlvenor is effective in the treatment of symptoms and signs of chronic venous insufficiency of the lower extremities.更多还原